


IN THE CLAIMS

1 (Currently Amended). A method for prevention of lipid peroxidation in the brain which comprises administering to an individual in need thereof an effective amount of a compound selected from the group consisting of:

(a) a compound of formula I:



wherein

R^1 is H or hydrocarbyl; R^2 is a hydrophobic radical; R^3 is a radical selected from the group consisting of 3-(C₂-C₆)acyl-4-hydroxyphenyl, 3-hydroxyimino(C₂-C₆)alkyl-4-hydroxyphenyl, ~~or~~ and COOZ, wherein Z is H, (C₁-C₆)alkyl, aryl or ar(C₁-C₆)alkyl; and n is an integer from 1 to 20; and

(b) a compound of formula II:



wherein

R^4 is (C₁-C₆)acyl, nitro(C₁-C₆)alkyl, cyano(C₁-C₆)alkyl, (C₁-C₆)alkoxy(C₁-C₆)alkyl or -CH₂NR⁷R⁸, wherein R⁷ and R⁸, the same or different, is each H or (C₁-C₆)alkyl, or

together with the N atom form a saturated or unsaturated 5-7 membered ring optionally containing a further heteroatom selected from the group consisting of N, O ~~or~~ and S, the further N atom in such saturated 5-7 membered ring being optionally substituted by (C₁-C₆)-alkyl, (C₁-C₆)-acyl, hydroxy-(C₁-C₆)alkyl, (C₁-C₆)alkoxycarbonyl, and 8-hydroxyquinolin-5-yl-(C₁-C₆)alkyl,

and

either R⁵ is H and R⁶ is (C₂-C₆)-acyl or hydroxyimino(C₂-C₆)alkyl, or R⁵ and R⁶ together with the phenyl ring form a quinoline, a 1,2,3,4-tetrahydroquinoline or a perhydroquinoline ring structure,

or a pharmaceutically acceptable salt of a compound of formula I or II.

2-3 (Cancelled)

4 (Currently Amended). A method according to claim 1, wherein said compound is a compound of formula I wherein n is 2 to 4, ~~preferably 2~~; R¹ is H or a saturated, unsaturated or aromatic hydrocarbyl radical, ~~preferably selected from C₁-C₈ alkyl, C₂-C₈ alkenyl and phenyl~~; R² is a hydrophobic radical selected from the group consisting of (C₆-C₂₀)-alkyl, (C₆-C₂₀)-alkenyl, a radical selected from the group consisting of (C₅-C₂₀)-acyl, benzyloxycarbonyl, substituted benzyloxycarbonyl, (C₃-C₈)-alkoxycarbonyl, cycloalkoxycarbonyl

and aryloxy carbonyl, said radical being either linked directly to the N atom or through a (C₁-C₅)-alkylene chain, and N-substituted amino or 4-substituted-piperazin-1-yl linked to the N atom through a (C₁-C₅)-alkylene chain; and R³ is a radical selected from the group consisting of 3-(C₂-C₆)acyl-4-hydroxyphenyl, 3-hydroxyimino(C₂-C₆)alkyl-4-hydroxyphenyl, ~~or~~ and COOZ, wherein Z is H, (C₁-C₆)alkyl, aryl or ar(C₁-C₆)alkyl.

5 (Currently Amended). A method according to claim 4, ¹/_{wherein} R² is straight or branched (C₆-C₂₀)-alkyl or alkenyl; saturated or unsaturated (C₅-C₂₀)-carboxylic acyl linked directly to the N atom or through a (C₁-C₅)-alkylene chain; benzyloxycarbonyl or halo-substituted benzyloxycarbonyl, ~~such as o- and p-chloro-benzyloxycarbonyl, 2,4- and 2,6-dichlorobenzyloxycarbonyl,~~ linked directly to the N atom or through a (C₁-C₅)-alkylene chain; a bulky alkoxy carbonyl group, ~~such as tert-butoxycarbonyl~~ linked directly to the N atom or through a (C₁-C₅)-alkylene chain; cycloalkoxy carbonyl linked directly to the N atom or through a (C₁-C₅)-alkylene chain; aryloxy carbonyl ~~such as fluorenylmethoxycarbonyl,~~ linked directly to the N atom or through a (C₁-C₅)-alkylene chain; or 4-substituted-piperazin-1-yl or N-substituted amino, linked to the N atom through a (C₁-C₅)-alkylene chain, wherein the 4- and N-substituent is a hydrophobic group selected from the group consisting of (C₆-C₂₀)-alkyl, (C₆-C₂₀)-alkenyl, (C₅-C₂₀)-acyl,

benzyloxycarbonyl, substituted benzyloxycarbonyl,
(C₃-C₈)-alkoxycarbonyl, cycloalkoxycarbonyl, aryloxycarbonyl,
N-substituted amino and 4-substituted-piperazin-1-yl, all
such substituents being as defined above.

6 (Currently Amended). A method according to claim
5, wherein n is 2, R¹ is H, R² is ~~a~~ the radical -
(CH₂)₃NHCOOCH₂C₆H₅, 5-(tert-butoxycarbonyl) pentyl, or -(CH₂)₂-
(4-carbobenzoxyl)-piperazin-1-yl, and R³ is benzyloxycarbonyl,
3-(1-hydroxy-iminoethyl)-4-hydroxyphenyl or 3-acetyl-4-
hydroxyphenyl.

7 (Previously Amended). A method according to claim
6, wherein said compound of formula I is selected from the
group of compounds consisting of:

N-[2-(4-carbobenzoxypiperazin-1-yl)ethyl]-4,5-
bis[bis(benzyloxycarbonylmethyl)amino]valeramide;

N-(3-benzyloxycarbonylaminopropyl)-4,5-bis[bis(3-
acetyl-4-hydroxybenzyl)amino]valeramide;

N-(3-benzyloxycarbonylaminopropyl)-4,5-bis[bis(3-(1-
hydroxy-iminoethyl)-4-hydroxybenzyl)amino]valeramide; and

N-[5-(tert-butyloxycarbonyl)pentyl]-4,5-
bis[(bis(benzyloxycarbonyl)methyl)amino]valeramide.

8 (Currently Amended). A method according to claim
1, wherein said compound is a compound of formula II wherein R⁴
is (C₁-C₆)-acyl, nitro(C₁-C₆)alkyl in which the (C₁-C₆)alkyl

group may be branched, cyano(C₁-C₆)alkyl, preferably
cyanomethyl, (C₁-C₆)-alkoxy(C₁-C₆)alkyl, preferably
methoxymethyl, or CH₂NR⁷R⁸, in which R⁷ and R⁸ are both H, or
one is H and the other is (C₁-C₆)-alkyl, or both R⁷ and R⁸ are
(C₁-C₆) alkyl, or R⁷ and R⁸ together with the N-atom form a
saturated or unsaturated 5-7 membered ring optionally
containing a further heteroatom selected from the group
consisting of N, O ~~or~~ and S, the further N-atom in such
saturated 5-7 membered ring being optionally substituted by
(C₁-C₆)-alkyl, (C₁-C₆)-acyl, hydroxy-(C₁-C₆)alkyl,
(C₁-C₆)-alkoxycarbonyl, ~~and or~~ 8-hydroxyquinolin-5-yl(C₁-C₆)
alkyl, ~~preferably 8-hydroxyquinolin-5-yl-methyl.~~

9 (Currently Amended). A method according to claim
8, wherein R⁴ is a radical selected from the group consisting
of formyl, 2-methyl-2-nitropropyl, cyanomethyl, methoxymethyl,
(diethyl)amino-methyl, piperidin-1-ylmethyl, morpholin-1-
ylmethyl, thiomorpholin-1-ylmethyl, piperazin-1-ylmethyl,
imidazolylmethyl, 4-methyl-piperazin-1-ylmethyl, 4-(2-
hydroxyethyl)piperazin-1-ylmethyl, 4-formylpiperazin-1-
ylmethyl, 4-(ethoxycarbonyl)piperazin-1-ylmethyl, 4-
(butoxycarbonyl) piperazin-1-ylmethyl, 4-(8-hydroxyquinolin-
5-yl-methyl)-piperazin-1-ylmethyl, and 4-(8-hydroxy-quinolin-
5-yl-methyl) homopiperazin-1-ylmethyl.

10 (Currently Amended). A method according to claim 8 or 9, wherein, in said compound of formula II, R^5 is H and R^6 is (C_2-C_6) -acyl, ~~preferably acetyl~~, or hydroxyimino (C_2-C_6) alkyl, ~~preferably hydroxyiminoethyl~~.

11 (Previously Amended). A method according to claim 10, wherein said compound of formula II is selected from the group of compounds consisting of::

2-acetyl-4-[4-(2-hydroxyethyl)piperazin-1-yl-methyl]phenol; and

2-(1-hydroxyiminoethyl)-4-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]phenol.

12 (Currently Amended). A method according to claim 8 or 9, wherein, in said compound of formula II, R^5 and R^6 together with the phenyl ring form a quinoline ring structure.

13 (Currently Amended). A method according to claim 12, wherein said quinoline compound is selected from the group consisting of:

5-formyl-8-hydroxyquinoline;

5-(2-methyl-2-nitropropyl)-8-hydroxyquinoline;

5-methoxymethyl-8-hydroxyquinoline;

5-diethylaminomethyl-8-hydroxyquinoline;

5-piperidinomethyl-8-hydroxyquinoline;

5-morpholinomethyl-8-hydroxyquinoline;

5-(4-methylpiperazin-1-ylmethyl)-8-hydroxyquinoline;

5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxy-quinoline;

5-[4-ethoxycarbonylpiperazin-1-ylmethyl)-8-hydroxy-quinoline;

5-(imidazol-1-ylmethyl)-8-hydroxyquinolin;

5-(4-Boc-piperazin-1-ylmethyl)-8-hydroxyquinoline;

5-piperazin-1-ylmethyl-8-hydroxyquinoline;

N,N'-di-(8-hydroxyquinolin-5-ylmethyl) piperazine;

5-(4-formylpiperazin-1-ylmethyl)-8-hydroxyquinoline;

5-cyanomethyl-8-hydroxyquinoline;

N,N'-di-(8-hydroxyquinolin-5-ylmethyl)

homopiperazine; and

5-thiomorpholin-1-ylmethyl-8-hydroxyquinoline.

14 (Cancelled)


15 (Previously Amended). A method according to claim 1 for the treatment of a neurodegenerative disorder.

16 (Previously Amended). A method according to claim 15 wherein said neurodegenerative disorder is Parkinson's disease.

17 (Previously Amended). A method according to claim 1 for the treatment of stroke.


18-21 (Cancelled)

22 (Currently Amended). A compound of formula I:



wherein

C₁
C₂
C₃
C₄
C₅
C₆
C₇
C₈
C₉
C₁₀
C₁₁
C₁₂
C₁₃
C₁₄
C₁₅
C₁₆
C₁₇
C₁₈
C₁₉
C₂₀
C₂₁
C₂₂
C₂₃
C₂₄
C₂₅
C₂₆
C₂₇
C₂₈
C₂₉
C₃₀
C₃₁
C₃₂
C₃₃
C₃₄
C₃₅
C₃₆
C₃₇
C₃₈
C₃₉
C₄₀
C₄₁
C₄₂
C₄₃
C₄₄
C₄₅
C₄₆
C₄₇
C₄₈
C₄₉
C₅₀
C₅₁
C₅₂
C₅₃
C₅₄
C₅₅
C₅₆
C₅₇
C₅₈
C₅₉
C₆₀
C₆₁
C₆₂
C₆₃
C₆₄
C₆₅
C₆₆
C₆₇
C₆₈
C₆₉
C₇₀
C₇₁
C₇₂
C₇₃
C₇₄
C₇₅
C₇₆
C₇₇
C₇₈
C₇₉
C₈₀
C₈₁
C₈₂
C₈₃
C₈₄
C₈₅
C₈₆
C₈₇
C₈₈
C₈₉
C₉₀
C₉₁
C₉₂
C₉₃
C₉₄
C₉₅
C₉₆
C₉₇
C₉₈
C₉₉
C₁₀₀
C₁₀₁
C₁₀₂
C₁₀₃
C₁₀₄
C₁₀₅
C₁₀₆
C₁₀₇
C₁₀₈
C₁₀₉
C₁₁₀
C₁₁₁
C₁₁₂
C₁₁₃
C₁₁₄
C₁₁₅
C₁₁₆
C₁₁₇
C₁₁₈
C₁₁₉
C₁₂₀
C₁₂₁
C₁₂₂
C₁₂₃
C₁₂₄
C₁₂₅
C₁₂₆
C₁₂₇
C₁₂₈
C₁₂₉
C₁₃₀
C₁₃₁
C₁₃₂
C₁₃₃
C₁₃₄
C₁₃₅
C₁₃₆
C₁₃₇
C₁₃₈
C₁₃₉
C₁₄₀
C₁₄₁
C₁₄₂
C₁₄₃
C₁₄₄
C₁₄₅
C₁₄₆
C₁₄₇
C₁₄₈
C₁₄₉
C₁₅₀
C₁₅₁
C₁₅₂
C₁₅₃
C₁₅₄
C₁₅₅
C₁₅₆
C₁₅₇
C₁₅₈
C₁₅₉
C₁₆₀
C₁₆₁
C₁₆₂
C₁₆₃
C₁₆₄
C₁₆₅
C₁₆₆
C₁₆₇
C₁₆₈
C₁₆₉
C₁₇₀
C₁₇₁
C₁₇₂
C₁₇₃
C₁₇₄
C₁₇₅
C₁₇₆
C₁₇₇
C₁₇₈
C₁₇₉
C₁₈₀
C₁₈₁
C₁₈₂
C₁₈₃
C₁₈₄
C₁₈₅
C₁₈₆
C₁₈₇
C₁₈₈
C₁₈₉
C₁₉₀
C₁₉₁
C₁₉₂
C₁₉₃
C₁₉₄
C₁₉₅
C₁₉₆
C₁₉₇
C₁₉₈
C₁₉₉
C₂₀₀
C₂₀₁
C₂₀₂
C₂₀₃
C₂₀₄
C₂₀₅
C₂₀₆
C₂₀₇
C₂₀₈
C₂₀₉
C₂₁₀
C₂₁₁
C₂₁₂
C₂₁₃
C₂₁₄
C₂₁₅
C₂₁₆
C₂₁₇
C₂₁₈
C₂₁₉
C₂₂₀
C₂₂₁
C₂₂₂
C₂₂₃
C₂₂₄
C₂₂₅
C₂₂₆
C₂₂₇
C₂₂₈
C₂₂₉
C₂₃₀
C₂₃₁
C₂₃₂
C₂₃₃
C₂₃₄
C₂₃₅
C₂₃₆
C₂₃₇
C₂₃₈
C₂₃₉
C₂₄₀
C₂₄₁
C₂₄₂
C₂₄₃
C₂₄₄
C₂₄₅
C₂₄₆
C₂₄₇
C₂₄₈
C₂₄₉
C₂₅₀
C₂₅₁
C₂₅₂
C₂₅₃
C₂₅₄
C₂₅₅
C₂₅₆
C₂₅₇
C₂₅₈
C₂₅₉
C₂₆₀
C₂₆₁
C₂₆₂
C₂₆₃
C₂₆₄
C₂₆₅
C₂₆₆
C₂₆₇
C₂₆₈
C₂₆₉
C₂₇₀
C₂₇₁
C₂₇₂
C₂₇₃
C₂₇₄
C₂₇₅
C₂₇₆
C₂₇₇
C₂₇₈
C₂₇₉
C₂₈₀
C₂₈₁
C₂₈₂
C₂₈₃
C₂₈₄
C₂₈₅
C₂₈₆
C₂₈₇
C₂₈₈
C₂₈₉
C₂₉₀
C₂₉₁
C₂₉₂
C₂₉₃
C₂₉₄
C₂₉₅
C₂₉₆
C₂₉₇
C₂₉₈
C₂₉₉
C₃₀₀
C₃₀₁
C₃₀₂
C₃₀₃
C₃₀₄
C₃₀₅
C₃₀₆
C₃₀₇
C₃₀₈
C₃₀₉
C₃₁₀
C₃₁₁
C₃₁₂
C₃₁₃
C₃₁₄
C₃₁₅
C₃₁₆
C₃₁₇
C₃₁₈
C₃₁₉
C₃₂₀
C₃₂₁
C₃₂₂
C₃₂₃
C₃₂₄
C₃₂₅
C₃₂₆
C₃₂₇
C₃₂₈
C₃₂₉
C₃₃₀
C₃₃₁
C₃₃₂
C₃₃₃
C₃₃₄
C₃₃₅
C₃₃₆
C₃₃₇
C₃₃₈
C₃₃₉
C₃₄₀
C₃₄₁
C₃₄₂
C₃₄₃
C₃₄₄
C₃₄₅
C₃₄₆
C₃₄₇
C₃₄₈
C₃₄₉
C₃₅₀
C₃₅₁
C₃₅₂
C₃₅₃
C₃₅₄
C₃₅₅
C₃₅₆
C₃₅₇
C₃₅₈
C₃₅₉
C₃₆₀
C₃₆₁
C₃₆₂
C₃₆₃
C₃₆₄
C₃₆₅
C₃₆₆
C₃₆₇
C₃₆₈
C₃₆₉
C₃₇₀
C₃₇₁
C₃₇₂
C₃₇₃
C₃₇₄
C₃₇₅
C₃₇₆
C₃₇₇
C₃₇₈
C₃₇₉
C₃₈₀
C₃₈₁
C₃₈₂
C₃₈₃
C₃₈₄
C₃₈₅
C₃₈₆
C₃₈₇
C₃₈₈
C₃₈₉
C₃₉₀
C₃₉₁
C₃₉₂
C₃₉₃
C₃₉₄
C₃₉₅
C₃₉₆
C₃₉₇
C₃₉₈
C₃₉₉
C₄₀₀
C₄₀₁
C₄₀₂
C₄₀₃
C₄₀₄
C₄₀₅
C₄₀₆
C₄₀₇
C₄₀₈
C₄₀₉
C₄₁₀
C₄₁₁
C₄₁₂
C₄₁₃
C₄₁₄
C₄₁₅
C₄₁₆
C₄₁₇
C₄₁₈
C₄₁₉
C₄₂₀
C₄₂₁
C₄₂₂
C₄₂₃
C₄₂₄
C₄₂₅
C₄₂₆
C₄₂₇
C₄₂₈
C₄₂₉
C₄₃₀
C₄₃₁
C₄₃₂
C₄₃₃
C₄₃₄
C₄₃₅
C₄₃₆
C₄₃₇
C₄₃₈
C₄₃₉
C₄₄₀
C₄₄₁
C₄₄₂
C₄₄₃
C₄₄₄
C₄₄₅
C₄₄₆
C₄₄₇
C₄₄₈
C₄₄₉
C₄₅₀
C₄₅₁
C₄₅₂
C₄₅₃
C₄₅₄
C₄₅₅
C₄₅₆
C₄₅₇
C₄₅₈
C₄₅₉
C₄₆₀
C₄₆₁
C₄₆₂
C₄₆₃
C₄₆₄
C₄₆₅
C₄₆₆
C₄₆₇
C₄₆₈
C₄₆₉
C₄₇₀
C₄₇₁
C₄₇₂
C₄₇₃
C₄₇₄
C₄₇₅
C₄₇₆
C₄₇₇
C₄₇₈
C₄₇₉
C₄₈₀
C₄₈₁
C₄₈₂
C₄₈₃
C₄₈₄
C₄₈₅
C₄₈₆
C₄₈₇
C₄₈₈
C₄₈₉
C₄₉₀
C₄₉₁
C₄₉₂
C₄₉₃
C₄₉₄
C₄₉₅
C₄₉₆
C₄₉₇
C₄₉₈
C₄₉₉
C₅₀₀
C₅₀₁
C₅₀₂
C₅₀₃
C₅₀₄
C₅₀₅
C₅₀₆
C₅₀₇
C₅₀₈
C₅₀₉
C₅₁₀
C₅₁₁
C₅₁₂
C₅₁₃
C₅₁₄
C₅₁₅
C₅₁₆
C₅₁₇
C₅₁₈
C₅₁₉
C₅₂₀
C₅₂₁
C₅₂₂
C₅₂₃
C₅₂₄
C₅₂₅
C₅₂₆
C₅₂₇
C₅₂₈
C₅₂₉
C₅₃₀
C₅₃₁
C₅₃₂
C₅₃₃
C₅₃₄
C₅₃₅
C₅₃₆
C₅₃₇
C₅₃₈
C₅₃₉
C₅₄₀
C₅₄₁
C₅₄₂
C₅₄₃
C₅₄₄
C₅₄₅
C₅₄₆
C₅₄₇
C₅₄₈
C₅₄₉
C₅₅₀
C₅₅₁
C₅₅₂
C₅₅₃
C₅₅₄
C₅₅₅
C₅₅₆
C₅₅₇
C₅₅₈
C₅₅₉
C₅₆₀
C₅₆₁
C₅₆₂
C₅₆₃
C₅₆₄
C₅₆₅
C₅₆₆
C₅₆₇
C₅₆₈
C₅₆₉
C₅₇₀
C₅₇₁
C₅₇₂
C₅₇₃
C₅₇₄
C₅₇₅
C₅₇₆
C₅₇₇
C₅₇₈
C₅₇₉
C₅₈₀
C₅₈₁
C₅₈₂
C₅₈₃
C₅₈₄
C₅₈₅
C₅₈₆
C₅₈₇
C₅₈₈
C₅₈₉
C₅₉₀
C₅₉₁
C₅₉₂
C₅₉₃
C₅₉₄
C₅₉₅
C₅₉₆
C₅₉₇
C₅₉₈
C₅₉₉
C₆₀₀
C₆₀₁
C₆₀₂
C₆₀₃
C₆₀₄
C₆₀₅
C₆₀₆
C₆₀₇
C₆₀₈
C₆₀₉
C₆₁₀
C₆₁₁
C₆₁₂
C₆₁₃
C₆₁₄
C₆₁₅
C₆₁₆
C₆₁₇
C₆₁₈
C₆₁₉
C₆₂₀
C₆₂₁
C₆₂₂
C₆₂₃
C₆₂₄
C₆₂₅
C₆₂₆
C₆₂₇
C₆₂₈
C₆₂₉
C₆₃₀
C₆₃₁
C₆₃₂
C₆₃₃
C₆₃₄
C₆₃₅
C₆₃₆
C₆₃₇
C₆₃₈
C₆₃₉
C₆₄₀
C₆₄₁
C₆₄₂
C₆₄₃
C₆₄₄
C₆₄₅
C₆₄₆
C₆₄₇
C₆₄₈
C₆₄₉
C₆₅₀
C₆₅₁
C₆₅₂
C₆₅₃
C₆₅₄
C₆₅₅
C₆₅₆
C₆₅₇
C₆₅₈
C₆₅₉
C₆₆₀
C₆₆₁
C₆₆₂
C₆₆₃
C₆₆₄
C₆₆₅
C₆₆₆
C₆₆₇
C₆₆₈
C₆₆₉
C₆₇₀
C₆₇₁
C₆₇₂
C₆₇₃
C₆₇₄
C₆₇₅
C₆₇₆
C₆₇₇
C₆₇₈
C₆₇₉
C₆₈₀
C₆₈₁
C₆₈₂
C₆₈₃
C₆₈₄
C₆₈₅
C₆₈₆
C₆₈₇
C₆₈₈
C₆₈₉
C₆₉₀
C₆₉₁
C₆₉₂
C₆₉₃
C₆₉₄
C₆₉₅
C₆₉₆
C₆₉₇
C₆₉₈
C₆₉₉
C₇₀₀
C₇₀₁
C₇₀₂
C₇₀₃
C₇₀₄
C₇₀₅
C₇₀₆
C₇₀₇
C₇₀₈
C₇₀₉
C₇₁₀
C₇₁₁
C₇₁₂
C₇₁₃
C₇₁₄
C₇₁₅
C₇₁₆
C₇₁₇
C₇₁₈
C₇₁₉
C₇₂₀
C₇₂₁
C₇₂₂
C₇₂₃
C₇₂₄
C₇₂₅
C₇₂₆
C₇₂₇
C₇₂₈
C₇₂₉
C₇₃₀
C₇₃₁
C₇₃₂
C₇₃₃
C₇₃₄
C₇₃₅
C₇₃₆
C₇₃₇
C₇₃₈
C₇₃₉
C₇₄₀
C₇₄₁
C₇₄₂
C₇₄₃
C₇₄₄
C₇₄₅
C₇₄₆
C₇₄₇
C₇₄₈
C₇₄₉
C₇₅₀
C₇₅₁
C₇₅₂
C₇₅₃
C₇₅₄
C₇₅₅
C₇₅₆
C₇₅₇
C₇₅₈
C₇₅₉
C₇₆₀
C₇₆₁
C₇₆₂
C₇₆₃
C₇₆₄
C₇₆₅
C₇₆₆
C₇₆₇
C₇₆₈
C₇₆₉
C₇₇₀
C₇₇₁
C₇₇₂
C₇₇₃
C₇₇₄
C₇₇₅
C₇₇₆
C₇₇₇
C₇₇₈
C₇₇₉
C₇₈₀
C₇₈₁
C₇₈₂
C₇₈₃
C₇₈₄
C₇₈₅
C₇₈₆
C₇₈₇
C₇₈₈
C₇₈₉
C₇₉₀
C₇₉₁
C₇₉₂
C₇₉₃
C₇₉₄
C₇₉₅
C₇₉₆
C₇₉₇
C₇₉₈
C₇₉₉
C₈₀₀
C₈₀₁
C₈₀₂
C₈₀₃
C₈₀₄
C₈₀₅
C₈₀₆
C₈₀₇
C₈₀₈
C₈₀₉
C



(II)

wherein

Amend

R⁴ is (C₁-C₆)acyl, nitro(C₁-C₆)alkyl, cyano(C₁-C₆)alkyl, (C₁-C₆)alkoxy(C₁-C₆)alkyl or -CH₂NR⁷R⁸, wherein R⁷ and R⁸, the same or different, is each H or (C₁-C₆)alkyl, or together with the N atom form a saturated or unsaturated 5-7 membered ring optionally containing a further heteroatom selected from N, O or S, the further N atom in such saturated 5-7 membered ring being optionally substituted by (C₁-C₆)-alkyl, (C₁-C₆)-acyl, hydroxy-(C₁-C₆)alkyl, (C₁-C₆)alkoxycarbonyl, and 8-hydroxyquinolin-5-yl-(C₁-C₆)alkyl, and


R⁵ is H and R⁶ is (C₂-C₆)-acyl or hydroxyimino(C₂-C₆)alkyl,

excluding the compounds:

2-hydroxy-5-(dipropylaminomethyl)acetophenone; and

2-hydroxy-5-(dipropylaminomethyl)acetophenone oxime.

24 (Currently Amended). A compound of formula II:



(II)

wherein

C₁-C₆
 R^4 is (C_1-C_6) acyl, nitro (C_1-C_6) alkyl, cyano (C_1-C_6) alkyl, (C_1-C_6) alkoxy (C_1-C_6) alkyl or $-CH_2NR^7R^8$, wherein R^7 and R^8 , the same or different, is each H or (C_1-C_6) alkyl, or together with the N atom form a saturated or unsaturated 5-7 membered ring optionally containing a further heteroatom selected from N, O or S, the further N atom in such saturated 5-7 membered ring being optionally substituted by (C_1-C_6) -alkyl, (C_1-C_6) -acyl, hydroxy- (C_1-C_6) alkyl, (C_1-C_6) alkoxycarbonyl, and 8-hydroxyquinolin-5-yl- (C_1-C_6) alkyl, and

R^5 and R^6 together with the phenyl ring form a quinoline, a 1,2,3,4-tetrahydroquinoline or a perhydroquinoline ring, excluding the quinoline compounds wherein R^4 is (C_1-C_2) acyl, cyanomethyl, (C_1-C_6) alkoxymethyl or $-CH_2NR^7NR^8$, wherein R^7 and R^8 are both H or (C_1-C_6) alkyl, or together with the N atom form a saturated ring selected from the group consisting of pyrrolidino, piperidino, morpholino and piperazino.

25 (New). The compound of claim 22 ~~/~~consisting of N-(3-benzyloxycarbonylaminopropyl)-4,5-bis[bis(3-(1-hydroxyiminoethyl)-4-hydroxybenzyl) amino] valeramide.

26 (New). The compound of claim 24 ~~/~~consisting of 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxyquinoline.

27 (New). A method according to claim 13 ~~/~~ which comprises administering to an individual in need thereof an effective amount of the compound 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxyquinoline.

28 (New). A method according to claim 27 ~~/~~for the treatment of stroke.

29 (New). A method according to claim 27 ~~/~~for the treatment of a neurodegenerative disorder.

30 (New). A method according to claim 29 ~~/~~wherein said neurodegenerative disorder is Parkinson's disease.

31 (New). A method for retarding dopaminergic neuron degeneration in the substantia nigra of the brain which comprises administering to an individual in need thereof an effective amount of the compound 5-[4-(2-hydroxyethyl)piperazin-1-ylmethyl]-8-hydroxyquinoline.

32 (New). A method according to claim 31 ~~/~~for the treatment of a neurodegenerative disorder.

33 (New). A method according to claim 32 ~~/~~wherein said neurodegenerative disorder is Parkinson's disease.